Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Annals medicus

• Publication date

  2003-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/07853890310001339PMID 12952023
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mast cells and angiogenesis

  2003cited by this paper
• Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

  2002cited by this paper
• Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study.

  2002cited by this paper
• Histamine stimulates matrix metalloproteinase-3 and -13 production by human articular chondrocytes in vitro

  2002cited by this paper
• Diagnosis of gastrointestinal stromal tumors: A consensus approach.

  2002cited by this paper
• Mast cells and angiogenesis

  2002cited by this paper
• Mast Cells: A Cellular Link Between Autoantibodies and Inflammatory Arthritis

  2002cited by this paper
• Methotrexate treatment and mortality in rheumatoid arthritis.

  2002cited by this paper
• Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

  2001cited by this paper
• Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

  2001cited by this paper
• Detection and quantitation of stem cell factor (kit ligand) in the synovial fluid of patients with rheumatic disease.

  2000cited by this paper
• Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

  2000cited by this paper
• Glucocorticoids inhibit the cytokine-induced proliferation of mast cells, the high affinity IgE receptor-mediated expression of TNF-alpha, and the IL-10-induced expression of chymases.

  1997cited by this paper
• Mast cell responses in rheumatoid synovium. Association of the MCTC subset with matrix turnover and clinical progression.

  1997cited by this paper
• Leukocyte-endothelial cell interactions evoked by mast cells.

  1996cited by this paper
• Mast cells and tumor-associated angiogenesis.

  1995cited by this paper
• Mast cells, cytokines, and metalloproteinases at the rheumatoid lesion: dual immunolocalisation studies.

  1995cited by this paper
• Induction by IL-9 and suppression by IL-3 and IL-4 of the levels of chromosome 14-derived transcripts that encode late-expressed mouse mast cell proteases.

  1993cited by this paper
• Regulation of mouse peritoneal mast cell secretory function by stem cell factor, IL-3 or IL-4.

  1993cited by this paper
• IL-3-dependent murine mast cells undergo apoptosis on removal of IL-3. Prevention of apoptosis by c-kit ligand.

  1993cited by this paper
• The kit ligand: a cell surface molecule altered in steel mutant fibroblasts.

  1990cited by this paper
• Revised criteria for the classification of rheumatoid arthritis.

  1990cited by this paper
• Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin.

  1990cited by this paper
• Mast cells as a source of both preformed and immunologically inducible TNF-α/cachectin

  1990cited by this paper
• Inhibition of histamine and prostaglandin D2 release from human lung mast cells by ciclosporin A.

  1989cited by this paper
• The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

  1988cited by this paper
• Articular mastocytosis in rheumatoid arthritis.

  1984cited by this paper
• The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales.

  1982cited by this paper

• Nanotechnology in Ankylosing Spondylitis: Advancements in Drug Delivery and Targeted Therapy

  2024cites this paper
• Single-cell computational machine learning approaches to immune-mediated inflammatory disease: New tools uncover novel fibroblast and macrophage interactions driving pathogenesis

  2023cites this paper
• Anti‐SARS‐CoV‐2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID‐19 therapy

  2022cites this paper
• Leveraging the Exploratory and Predictive Capabilities of Design of Experiments in Development of Intraarticular Injection of Imatinib Mesylate Containing Lipospheres

  2022cites this paper
• Follicular dendritic cell differentiation is associated with distinct synovial pathotype signatures in rheumatoid arthritis

  2022cites this paper
• Safety, tolerability, and pharmacokinetics of single and multiple topical ophthalmic administration of imatinib mesylate in healthy subjects

  2022cites this paper
• The Binary Classification of Protein Kinases

  2021cites this paper
• Summarizing current refractory disease definitions in rheumatoid arthritis and polyarticular juvenile idiopathic arthritis: systematic review

  2021cites this paper
• In Vivo Efficacy of Imatinib Mesylate, a Tyrosine Kinase Inhibitor, in the Treatment of Chemically Induced Dry Eye in Animal Models

  2021cites this paper
• Preparation and Evaluation of Imatinib Loaded Transfersomal gel for the Treatment of Rheumatoid Arthritis

  2021cites this paper
• Repurposing of Kinase Inhibitors for Treatment of COVID-19

  2020cites this paper
• The potential effect of imatinib against hypercholesterolemia induced atherosclerosis, endothelial dysfunction and hepatic injury in rabbits.

  2020cites this paper
• Paradigm Shifts in Mast Cell and Basophil Biology and Function: An Emerging View of Immune Regulation in Health and Disease.

  2020cites this paper
• Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts

  2020cites this paper
• Imatinib in Refractory Crohn Disease: A Series of 6 Cases

  2019cites this paper
• KIT as a therapeutic target for non‐oncological diseases

  2019cites this paper
• Long-term management of canine disseminated granulomatous meningoencephalitis with imatinib mesylate: a case report

  2019cites this paper
• Imatinib inhibits CSF1R that stimulates proliferation of rheumatoid arthritis fibroblast‐like synoviocytes

  2018cites this paper
• The tyrosine kinase inhibitor imatinib mesylate suppresses uric acid crystal-induced acute gouty arthritis in mice

  2017cites this paper
• Idiopathic Arthritis Hodgkin's Lymphoma and Tumor Necrosis Factor Inhibitors in Juvenile

  2017cites this paper
• L’activation du PDGFR favorise le phénotype agressif des synoviocytes de patients atteints de polyarthrite rhumatoïde via la formation d’invadosomes

  2017cites this paper
• Rituximab for Refractory Myositis Severe Nontuberculous Mycobacterial Infection in 2 Patients Receiving

  2017cites this paper
• ACTIVATION OF HUMAN MAST CELLS TO DOWN- REGULATE MONOCYTE-MEDIATED IMMUNE RESPONSES Chapter 6

  2016cites this paper
• Effet de l’Imatinib dans la maladie de Crohn réfractaire : revue de 6 cas

  2016cites this paper
• Platelet-Derived Growth Factor Receptor Activation Promotes the Prodestructive Invadosome-Forming Phenotype of Synoviocytes from Patients with Rheumatoid Arthritis

  2016cites this paper
• This information is current as Arthritis Synoviocytes from Patients with Rheumatoid Invadosome-Forming Phenotype of Activation Promotes the Prodestructive Platelet-Derived Growth Factor Receptor

  2016cites this paper
• Ability of Interleukin‐33– and Immune Complex–Triggered Activation of Human Mast Cells to Down‐Regulate Monocyte‐Mediated Immune Responses

  2015cites this paper
• articlePlatelet-derived growth factor and transforming growth factor beta synergistically potentiate inflammatory mediator synthesis by fibroblast-like synoviocytes

  2015cites this paper
• Environmental Factors Involved in the Pathogenesis of Systemic Lupus Erythematosus

  2014cites this paper
• Hypereosinophilia and Seroconversion of Rheumatoid Arthritis

  2014cites this paper
• Synthesis of Heterocyclic Compounds

  2014cites this paper
• Targeting mast cells in inflammatory diseases.

  2014cites this paper
• Progress in tuberculosis vaccine development and host-directed therapies--a state of the art review.

  2014cites this paper
• Paradigm shifts in mast cell and basophil biology and function: an emerging view of immune regulation in health and disease.

  2014cites this paper
• Molecular targets on mast cells and basophils for novel therapies.

  2014cites this paper
• Protein kinase Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases

  2014cites this paper
• Effect of tyrosine kinase inhibitors, imatinib and nilotinib, in murine lipopolysaccharide-induced acute lung injury during neutropenia recovery

  2013cites this paper
• Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor

  2013cites this paper
• Induction of Rheumatoid Arthritis and Response to Tyrosine Kinase Inhibitors

  2013cites this paper
• Non-professional histamine producing cells, immune responses and autoimmunity

  2013influential citation
• Targeting c-kit in the therapy of mast cell disorders: current update.

  2012cites this paper
• Cellular Targeting in Autoimmunity

  2012cites this paper
• Composés et compositions pouvant être utilisés en tant qu'inhibiteurs des kinases pdgfr

  2012cites this paper
• Effect of Nilotinib on Bleomycin-Induced Acute Lung Injury and Pulmonary Fibrosis in Mice

  2011cites this paper
• Mast Cells as Cellular Sensors in Inflammation and Immunity

  2011cites this paper
• Efficacy of Imatinib Mesylate Treatment for a Patient with Rheumatoid Arthritis and Who Developed Chronic Myelogenous Leukemia

  2011cites this paper
• Tirosin Kinase Inhibitors in Chronic Graft versus Host Disease: From Bench to Bedside

  2011cites this paper
• Comparative suppressive effects of tyrosine kinase inhibitors imatinib and nilotinib in models of autoimmune arthritis

  2011cites this paper
• Comparative suppressive effects of tyrosine kinase inhibitors imatinib and nilotinib in models of autoimmune arthritis

  2011cites this paper
• Effect of Imatinib on Airway Smooth Muscle Thickening in a Murine Model of Chronic Asthma

  2011cites this paper
• Inhibition of fms‐like tyrosine kinase 3 alleviates experimental arthritis by reducing formation of dendritic cells and antigen presentation

  2011cites this paper
• Imatinib mesylate directly impairs class switch recombination through down-regulation of AID: its potential efficacy as an AID suppressor.

  2010cites this paper
• Imatinib mesylate induces clinical remission in rheumatoid arthritis.

  2010cites this paper
• A multitude of kinases--which are the best targets in treating rheumatoid arthritis?

  2010cites this paper
• Rémission clinique d’une polyarthrite rhumatoïde sous imatinib mésylate☆

  2010cites this paper
• c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis

  2010cites this paper
• Role of Angiogenesis in the Pathogenesis of Arthritis: Potential Therapeutic Applications

  2010cites this paper
• A Case of Ankylosing Spondylitis Accompanied by Chronic Myelogenous Leukemia

  2010cites this paper
• Platelet-derived growth factor and transforming growth factor beta synergistically potentiate inflammatory mediator synthesis by fibroblast-like synoviocytes

  2010cites this paper
• Title Platelet-derived growth factor and transforming growth factor beta synergistically potentiate inflammatory mediator synthesis by fibroblast-like synoviocytes

  2010cites this paper
• Imatinib treatment of ankylosing spondylitis in a patient resistant to NSAIDs and infliximab.

  2010cites this paper
• Garden of therapeutic delights: new targets in rheumatic diseases

  2009cites this paper
• Tyrosine kinases as targets for the treatment of rheumatoid arthritis

  2009cites this paper
• A glimpse into the future: recombinant proteins and small molecules for targeted therapies in rheumatic diseases.

  2009cites this paper
• Intracellular signal pathways: Potential for therapies

  2009influential citation
• Therapy in a Patient with Chronic Myelogenous Leukemia Longstanding Remission of Adult Onset Still ' s Disease Under Imatinib

  2009cites this paper
• Tyrosine kinases as targets in rheumatoid arthritis.

  2009cites this paper
• Chapter 10 Advances in the Discovery of Anti-Inflammatory FMS Inhibitors

  2009cites this paper
• Ethanol induces apoptosis in human mast cells.

  2009cites this paper
• More about masitinib

  2009cites this paper
• Longstanding Remission of Adult Onset Still’s Disease Under Imatinib Therapy in a Patient with Chronic Myelogenous Leukemia

  2009cites this paper
• Imatinib mesylate inhibited rat adjuvant arthritis and PDGF-dependent growth of synovial fibroblast via interference with the Akt signaling pathway

  2009cites this paper
• Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update.

  2008cites this paper
• Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice

  2008cites this paper
• Targeted therapy in rheumatoid arthritis

  2008cites this paper
• Maintained efficacy of the tyrosine kinase inhibitor imatinib mesylate in a patient with rheumatoid arthritis.

  2008cites this paper
• Idiopathic Arthritis Hodgkin ' s Lymphoma and Tumor Necrosis Factor Inhibitors in Juvenile

  2008cites this paper
• [A new therapeutic avenue for severe systemic sclerosis: imatinib mesylate].

  2008cites this paper
• Is there a role for imatinib in inflammatory bowel disease?

  2008cites this paper
• Imatinib treatment of seropositive arthritis in a young woman with chronic myeloid leukemia.

  2008cites this paper
• Both Etanercept and Infliximab Can Elevate Tumor Necrosis Factor (TNF)-α and Be the Cause of Treatment Related New Onset Disease: the Need to Measure Circulating TNF-α

  2008cites this paper
• Une nouvelle piste thrapeutique pour les sclrodermies graves : le msylate dimatinib

  2008cites this paper
• Imatinib for the treatment of rheumatic

  2007cites this paper
• Synovial mast cells: role in acute and chronic arthritis

  2007cites this paper
• Leflunomide Inhibits PDK1/Akt Pathway and Induces Apoptosis of Human Mast Cells1

  2007cites this paper
• Mast cells in the pathogenesis of rheumatic diseases and as potential targets for anti‐rheumatic therapy

  2007cites this paper
• Selective activation of mast cells in rheumatoid synovial tissue results in production of TNF-alpha, IL-1beta and IL-1Ra.

  2007cites this paper
• Selective activation of mast cells in rheumatoid synovial tissue results in production of TNF-α, IL-1β and IL-1Ra

  2007cites this paper
• [Imatinib mesylate as a novel therapeutic drug for systemic rheumatic diseases].

  2007cites this paper
• Imatinib mesylate both prevents and treats the arthritis induced by type II collagen antibody in mice

  2007cites this paper
• Imatinib for the treatment of rheumatic diseases

  2007cites this paper
• Induces Apoptosis of Human Mast Cells Leflunomide Inhibits PDK1/Akt Pathway and

  2007cites this paper
• Platelet-Derived Growth Factor as a Therapeutic Target for Systemic Autoimmune Diseases

  2007cites this paper
• Imatinib mesylate inhibits platelet derived growth factor stimulated proliferation of rheumatoid synovial fibroblasts.

  2006cites this paper
• Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis.

  2006cites this paper
• Serum amyloid A (SAA) activates human mast cells which leads into degradation of SAA and generation of an amyloidogenic SAA fragment.

  2006cites this paper
• Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA)

  2006influential citation
• Three months treatment of active spondyloarthritis with imatinib mesylate: an open-label pilot study with six patients.

  2006cites this paper
• Patient perception of UK scleroderma services—results of an anonymous questionnaire

  2006cites this paper
• Imatinib mesylate inhibits proliferation of rheumatoid synovial fibroblast‐like cells and phosphorylation of Gab adapter proteins activated by platelet‐derived growth factor

  2006cites this paper